Metajodobenzyloguanidyna-123i (Mibg-123i) Narodowe Centrum Badań Jądrowych

Iobenguane sulfate I-123, the active ingredient in Metajodobenzyloguanidyna-123i (Mibg-123i) Narodowe Centrum Badań Jądrowych, is a radiopharmaceutical presented as a sterile solution for injection for intravenous use. It is employed in nuclear medicine to image adrenergic tissue, aiding the detection of pheochromocytoma, neuroblastoma, and assessment of cardiac sympathetic innervation in adult patients.

GNH USA supplies Metajodobenzyloguanidyna-123i (Mibg-123i) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, nuclear medicine departments and diagnostic imaging clinics worldwide, ensuring regulatory‑approved quality and reliable cold‑chain logistics.

Metajodobenzyloguanidyna-123i (Iobenguane sulfate I-123) is a norepinephrine‑analogue tracer used in nuclear medicine to evaluate adrenergic tissue disorders and cardiac sympathetic function.

- Pheochromocytoma: enables precise scintigraphic detection and localization of catecholamine‑producing adrenal or extra‑adrenal tumors, supporting surgical planning. - Neuroblastoma: provides high‑contrast imaging of tumor uptake for staging, response assessment and therapeutic decision‑making in pediatric and adult patients. - Cardiac sympathetic innervation assessment: quantifies myocardial sympathetic nerve activity to aid risk stratification in heart failure and arrhythmia management.

Adverse reactions are generally mild but can occur after intravenous administration.

Common Side Effects: - Injection site pain: transient discomfort at the venipuncture site. - Transient flushing: brief warmth or redness. - Mild nausea: occasional upset stomach. - Headache: low‑grade headache lasting minutes to hours.

Serious or Rare Side Effects: - Allergic reaction (anaphylaxis): rapid onset of breathing difficulty, rash or swelling. - Severe hypotension: sudden drop in blood pressure requiring monitoring. - Radiation‑induced tissue injury: rare localized damage in high‑uptake organs.

Use of Metajodobenzyloguanidyna-123i requires careful patient assessment and adherence to handling standards. - Pregnancy: unknown safety; avoid unless the diagnostic benefit outweighs potential risk. - Breastfeeding: insufficient data; consider withholding milk or using alternative imaging. - Renal impairment: evaluate renal function as altered clearance may affect image quality. - Concomitant sympathomimetic drugs: may compete for NET and reduce tracer uptake. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iobenguane sulfate I-123 may have interactions that affect image quality or patient safety.

Major Interactions (Avoid): - Alpha‑adrenergic agonists: compete for NET, diminishing tracer accumulation. - Beta‑blockers: alter cardiac sympathetic imaging results. - High‑dose iodine contrast agents: can interfere with gamma detection and image interpretation.

Moderate Interactions (Monitor Closely): - MAO inhibitors: may modify catecholamine metabolism, influencing tracer distribution. - Antidepressants affecting norepinephrine reuptake: could change NET activity and affect imaging patterns.